Glenmede Trust’s Achillion Pharmaceuticals ACHN Stock Holding History

Glenmede Trust’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,074	Closed	-$5K	–	2452
2018 Q1	$5K	Hold	2,074	–	–	﹤0.01%	2421
2017 Q4	$5K	Buy	+2,074	New	+$7.54K	﹤0.01%	2421

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Glenmede Trust's ACHN Position: Q2 2018 in Review

Glenmede Trust sold out of Achillion Pharmaceuticals (ACHN) in Q2 2018, closing a stake of 2,074 shares — an estimated $5K sold.

Glenmede Trust first reported a position in ACHN in Q4 2017 and held it in 2 quarters. The position peaked at $5K in Q1 2018. 124 funds tracked by Wall St. Rank hold ACHN as of Q2 2018.

Glenmede Trust reported no remaining Achillion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Glenmede Trust sold 2,074 Achillion Pharmaceuticals shares in Q2 2018, an estimated $5K.
Glenmede Trust first reported a position in Achillion Pharmaceuticals in Q4 2017 and held it in 2 quarters.
Glenmede Trust's Achillion Pharmaceuticals position peaked at $5K in Q1 2018.
124 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2018.

Based on Glenmede Trust's 13F filing for Q2 2018, filed 15 Aug 2018.